Management team

Dirk Reyn has 24 years of pharma experience. He was Head of International Strategic Marketing for the Gastrointestinal Franchise at JNJ, a member of several Global Development Teams at Janssen Pharmaceutica, including prucalopride and Global Head of Prepulsid Regulatory Team. Further he builds on 10 years of sales management and commercial experience at Eli Lilly. His last position at Janssen Pharmaceutica was that of VP New Business Development and in-licensing Europe.

Jan Schuurkes has 30 years of drug discovery experience at Janssen Pharmaceutica and JNJ. He was the key or lead player in the discovery of cisapride, loperamide-oxide and domperidone and his last position at Janssen Pharmaceutica was that of Vice President of pre-clinical GI research.

Lieve Vandeplassche holds 25 years of clinical development experience of which 15 in GI at Janssen Pharmaceutica and Novartis. She was one of the International Project leaders for the early development of prucalopride at Janssen Pharmaceutica and later International Clinical Leader for the development of tegaserod in upper GI disorders at Novartis. Her last position was that of Head of Clinical Development at Barrier Therapeutics.

Catherine Moukheibir has17 years of financial industry experience including 6 years in pharma. She was management consultant at a number of leading firms based in Boston and London and Executive Director Investment Banking with Salomon Smith Barney and Morgan Stanley. Her last position was that of Director Capital Markets at Zeltia.

Pieter Korst has joined Movetis in October 2009 as Vice President Marketing & Customer Relations Management. He is bringing with him, 21 years of experience at Johnson & Johnson . His positions included Marketing Manager in the Netherlands, Managing Director in Egypt and Regional Marketing Manager and Head of Business Operations in Europe, Asia and MEWA. His most recent role was as the Executive Director of Strategic Marketing for Janssen-Cilag for the Eastern Europe and Middle East regions.

Ann Meulemans has 18 years of discovery and early development experience at Janssen Pharmaceutica. She was a key player in preclinical development of several of our GI compounds and the Head of GI and Emerging Diseases area at Janssen. Her last position was that of Head of Clinical Development for Internal Medicine in the European JNJ R&D organization.

Dirk Van Broekhoven holds18 years of pharma industry experience at Janssen Pharmaceutica, JNJ and Tibotec. He was the head of the regulatory law group within the JNJ Law Department Europe and his last position was that of Head of the Law Department at Tibotec-Virco.

Martine De Pauw  brings 14 years of experience in clinical development - mainly in the GI therapeutica area - to Movetis. She started her career at Janssen-Cilag and the Janssen Research Foundation, where she became Clinical Research Manager for prucalorpide and managed the phase II and III trials up to preparation for EMEA and FDA filing. In 2001, she moved to Tibotec-Virco, where she managed the clinical trial programmes for an HIV-therapy and an hepatitis C therapy.

Patricia Robinson has over 12 years of experience in R&D and pharmacovigilance. She started her industrial career at Laboratoires Hoechst Houdé and then moved to the Janssen Research Foundation where she was involvedi n clincial projects related to various GI compound. In 2001, she was promoted to Senior Director, Medial Evaluation Officer at Johnson & Johnson Pharmaceutical R&D, and in 2003 she became Vice President of the Benefit Risk management department.